Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

Completed

Conditions studied: Erosive Esophagitis, Reflux Esophagitis, GERD

In brief

This study is being done to for two reasons: * To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly. * To learn about the quality of life changes (good and bad) you may experience with this medication.

Key facts

Study ID

NCT00586963

Run by

Mayo Clinic

People needed

65

Starts

2008-01-01

Expected to finish

2008-12-01

Last updated by the study team

2010-08-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older
• Have either mild-to-moderate erosive reflux esophagitis
• Meet criteria for GERD symptoms.

You may not qualify if…

• Patients already on esomeprazole therapy, have previously failed to respond to esomeprazole, or are intolerant to PPI therapy.
• Patients expected to travel outside of the United States during the initial 8 weeks of PPI therapy.
• Pregnant women will be excluded as PPI's are not thought safe for the fetus (Pregnancy Category C). - Children younger than 18 years of age will be excluded.
• Other vulnerable populations, such as those with diminished mental acuity, will be excluded.

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.